

Resource Summary Report

Generated by [NIF](#) on Sep 12, 2026

Anti-RBM39 antibody produced in rabbit

RRID:AB_1079749

Type: Antibody

Proper Citation

Sigma-Aldrich Cat# HPA001591, RRID:AB_1079749

Antibody Information

URL: http://antibodyregistry.org/AB_1079749

Proper Citation: Sigma-Aldrich Cat# HPA001591, RRID:AB_1079749

Target Antigen: RBM39 antibody produced in rabbit

Host Organism: rabbit

Clonality: polyclonal

Comments: Vendor recommendations: Immunofluorescence; Other; Immunohistochemistry; Western Blot; indirect immunofluorescence: suitable, immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable, protein array: suitable, immunoblotting: suitable

Antibody Name: Anti-RBM39 antibody produced in rabbit

Description: This polyclonal targets RBM39 antibody produced in rabbit

Target Organism: human

Antibody ID: AB_1079749

Vendor: Sigma-Aldrich

Catalog Number: HPA001591

Record Creation Time: 20231110T074647+0000

Record Last Update: 20260829T023747+0000

Ratings and Alerts

- Antibody validation available from The Human Protein Atlas - Human Protein Atlas <https://www.proteinatlas.org/search/HPA001591>

No alerts have been found for Anti-RBM39 antibody produced in rabbit.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Ma Y, et al. (2026) Exploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degraders. Cell reports, 45(1), 116784.

Singh S, et al. (2025) RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity. Nature communications, 16(1), 8287.

Jablonowski CM, et al. (2024) Metabolic reprogramming of cancer cells by JMJD6-mediated pre-mRNA splicing associated with therapeutic response to splicing inhibitor. eLife, 12.

Xu Y, et al. (2023) Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma. Cell reports, 42(10), 113307.

Zhou J, et al. (2022) An oncogenic JMJD6-DGAT1 axis tunes the epigenetic regulation of lipid droplet formation in clear cell renal cell carcinoma. Molecular cell, 82(16), 3030.

Lu SX, et al. (2021) Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell, 184(15), 4032.

Gaucherand L, et al. (2019) The Influenza A Virus Endoribonuclease PA-X Usurps Host mRNA Processing Machinery to Limit Host Gene Expression. Cell reports, 27(3), 776.

Wang E, et al. (2019) Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia. Cancer cell, 35(3), 369.

Ting TC, et al. (2019) Aryl Sulfonamides Degrade RBM39 and RBM23 by Recruitment to CRL4-DCAF15. Cell reports, 29(6), 1499.